子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | Methods for producing crystalline microporous solids with a new CIT-7 topology and compositions derived from the same | US14602433 | 2015-01-22 | US09873113B2 | 2018-01-23 | Joel E. Schmidt; Mark E. Davis |
| This disclosure relates to new crystalline microporous solids (including silicate- and aluminosilicate-based solids), the compositions comprising 8 and 10 membered inorganic rings, particularly those having CIT-7 topologies having a range of Si:Al ratios, methods of preparing these and known crystalline microporous solids using certain quaternized imidazolium cation structuring agents. | ||||||
| 142 | Microporous zirconium silicate for the treatment of hyperkalemia | US14826038 | 2015-08-13 | US09861658B2 | 2018-01-09 | Donald Jeffrey Keyser; Alvaro F. Guillem |
| The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | ||||||
| 143 | Microporous zirconium silicate for the treatment of hyperkalemia | US14321659 | 2014-07-01 | US09844567B2 | 2017-12-19 | Donald Jeffrey Keyser; Alvaro F. Guillem |
| The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | ||||||
| 144 | Crystalline molecular sieves and synthesis thereof | US15215657 | 2016-07-21 | US09738537B2 | 2017-08-22 | Stacey Ian Zones |
| Crystalline molecular sieves and their synthesis using quaternary N-methyl-diisoalkylammonium cations as organic structure directing agents are disclosed. The structure directing agent has the following structure (1): in which R1 is selected from hydrogen, a methyl group, an ethyl group, a propyl group, and a hydroxymethyl group; and R2, R3, R4 and R5 are independently selected from a methyl group, an ethyl group, and a propyl group. | ||||||
| 145 | MOLECULAR ENCAPSULATION IN METAL-ORGANIC FRAMEWORK CRYSTALS | US15502551 | 2015-08-17 | US20170232420A1 | 2017-08-17 | Chia-Kuang Tsung; Jeffery Byers |
| The present invention provides novel host-guest complexes, wherein the guest molecule has a diameter larger than the aperture size of the host-a metal organic framework (MOF). The novel host-guest complexes of the invention can be used for drug delivery, sensing, electrical conductivity, luminescence, and energy conversion. The invention also provides a method of making the novel host-guest complex, utilizing the linker exchange conditions in which a guest molecule having a diameter larger than the aperture size of the host is encapsulated into the MOF. | ||||||
| 146 | Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia | US13939656 | 2013-07-11 | US09707255B2 | 2017-07-18 | Donald Jeffrey Keyser; Alvaro F. Guillem |
| The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without removing calcium from the patient's body. Also disclosed are methods of using calcium-free or low calcium microporous zirconium silicate compositions for the treatment of hyperkalemia in patients also suffering from hypercalcemia. | ||||||
| 147 | PROCESS FOR PRODUCING A MOLECULAR SIEVE HAVING THE SFE STRUCTURE, MOLECULAR SIEVE HAVING THE SFE STRUCTURE AND USE THEREOF | US15347142 | 2016-11-09 | US20170128924A1 | 2017-05-11 | Weimin YANG; Zhendong WANG; Hongmin SUN; Bin ZHANG; Yi LUO |
| The present invention relates to a molecular sieve having the SFE structure, a process for producing same and use thereof. The process includes a step of crystallizing a mixture comprising a first oxide source, a second oxide source, an organic template and water to obtain a molecular sieve having the SFE structure, wherein the organic template is preferably 4-dimethylamino pyridine. As compared with the prior art, the process exhibits such merits as significantly reduced crystallization duration. | ||||||
| 148 | SCM-11 MOLECULAR SIEVE, PROCESS FOR PRODUCING SAME AND USE THEREOF | US15347117 | 2016-11-09 | US20170128918A1 | 2017-05-11 | Weimin YANG; Zhendong WANG; Hongmin SUN; Bin ZHANG; Yi LUO |
| The present invention relates to an SCM-11 molecular sieve, a process for producing same and use thereof. The molecular sieve has an empirical chemical composition as illustrated by the formula “the first oxide·the second oxide”, wherein the ratio by molar of the first oxide to the second oxide is more than 2, the first oxide is silica, the second oxide is at least one selected from the group consisting of germanium dioxide, alumina, boron oxide, iron oxide, gallium oxide, titanium oxide, rare earth oxides, indium oxide and vanadium oxide. The molecular sieve has specific XRD pattern, and can be used as an adsorbent or a catalyst for converting an organic compound. | ||||||
| 149 | METAL-ORGANIC FRAMEWORKS CHARACTERIZED BY HAVING A LARGE NUMBER OF ADSORPTION SITES PER UNIT VOLUME | US15126395 | 2015-03-17 | US20170081345A1 | 2017-03-23 | Omar M. Yaghi; Felipe Gandara; Seungkyu Lee |
| The disclosure provides for metal organic frameworks characterized by having a high number of linking moieties connected to metal clusters and a large number of adsorption sites per unit volume. The disclosure further provides for the use of these frameworks for gas separation, gas storage, catalysis, and drug delivery. | ||||||
| 150 | SYNTHESIS AND CRYSTAL STRUCTURE OF IRON ZEOLITIC FRAMEWORKS | US15218742 | 2016-07-25 | US20170022067A1 | 2017-01-26 | Hans-Conrad zur Loye; William Michael Chance; Gregory Morrison |
| Iron-based crystal structures including FeO4 tetrahedrally coordinated in three dimensions in a framework analogous to a zeolite. The structures having the general formula AyB8Fe12O24(O/OH)6.xH2O in which A is Na, K, Cs, Rb or a combination thereof and B is an alkaline earth element or a combination of alkaline earth elements. | ||||||
| 151 | CIT-10: A TWO DIMENSIONAL LAYERED CRYSTALLINE MICROPOROUS SILICATE COMPOSITION AND COMPOSITIONS DERIVED THEREFROM | US15198219 | 2016-06-30 | US20170001872A1 | 2017-01-05 | JOEL E. SCHMIDT; MARK E. DAVIS |
| This disclosure relates to a new crystalline microporous silicate solid, designated CIT-10, comprising a two dimensional layered structure, having an organic interlayer sandwiched between individual crystalline silicate layers. This CIT-10 material can be converted to a pure-silicate of RTH topology, as well as two new of pillared silicate structures, designated CIT-11 and CIT-12. This disclosure characterizes new materials and provides methods of preparing and using these new crystalline microporous solids. | ||||||
| 152 | Hybrid zeolitic imidazolate frameworks: controlling framework porosity and functionality by a mixed-ligand synthetic approach | US13754430 | 2013-01-30 | US09527872B2 | 2016-12-27 | Joshua Allen Thompson; Catherine Rose Blad; Christopher W. Jones; Sankar Nair |
| Metal-organic frameworks, in particular hybrid zeolitic imidazolate frameworks (ZIFs), devices having hybrid ZIFs, and methods for preparing hybrid ZIFs are disclosed herein. In some embodiments, the method includes preparing a first solution comprising a first imidazolate and a second imidazolate, preparing a second solution comprising a metal ion, and combining the first solution and the second solution to form the hybrid ZIF. | ||||||
| 153 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA | US15254688 | 2016-09-01 | US20160367598A1 | 2016-12-22 | Donald Jeffrey KEYSER; Alvaro F. GUILLEM; Jeff GILMORE |
| The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | ||||||
| 154 | AROMATIC HYDROGENATION CATALYSTS AND USES THEREOF | US14966071 | 2015-12-11 | US20160167032A1 | 2016-06-16 | Paul Podsiadlo; Quanchang Li; David Charles Calabro; Jean Willem Lodewijk Beeckman; Lei Zhang; Kiara M. Benitez; Matthew Scott Ide; Stephen John McCarthy; Mobae Afeworki; Simon Christopher Weston |
| Hydrogenation catalysts for aromatic hydrogenation including an organosilica material support, which is a polymer comprising independent units of a monomer of Formula [Z1OZ2OSiCH2]3 (I), wherein each Z1 and Z2 independently represent a hydrogen atom, a C1-C4 alkyl group or a bond to a silicon atom of another monomer; and at least one catalyst metal are provided herein. Methods of making the hydrogenation catalysts and processes of using, e.g., aromatic hydrogenation, the hydrogenation catalyst are also provided herein. | ||||||
| 155 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia | US14826038 | 2015-08-13 | US20150342988A1 | 2015-12-03 | Donald Jeffrey KEYSER; Alvaro F. GUILLEM |
| The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | ||||||
| 156 | METHOD AND APPARATUS FOR PREPARING ZEOLITE | US14438566 | 2013-10-25 | US20150314278A1 | 2015-11-05 | Lingping ZHOU; Ziyang LIU; Jiexiao ZHANG; Mingde XU; Weilin ZHANG; Huiping TIAN; Yuxia ZHU |
| A process for preparing a catalytic cracking catalyst, which process comprises: a molecular sieve is introduced into a gas-phase ultra-stabilization reactor, the molecular sieve is moved without the conveying of carrier gas from a molecular sieve inlet of the gas-phase ultra-stabilization reactor to a molecular sieve outlet of the gas-phase ultra-stabilization reactor, and the molecular sieve is contacted and reacted with a gaseous SiCl4 in the gas-phase ultra-stabilization reactor, the molecular sieve resulting from the contacting and the reacting is optionally washed, then mixed with a matrix and water into slurry, and shaped into particles. | ||||||
| 157 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA | US14692287 | 2015-04-21 | US20150225249A1 | 2015-08-13 | Donald Jeffrey KEYSER; Alvaro F. GUILLEM |
| The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | ||||||
| 158 | NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH A NEW CIT-7 TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME | US14602433 | 2015-01-22 | US20150203357A1 | 2015-07-23 | JOEL E. SCHMIDT; MARK E. DAVIS |
| This disclosure relates to new crystalline microporous solids (including silicate- and aluminosilicate-based solids), the compositions comprising 8 and 10 membered inorganic rings, particularly those having CIT-7 topologies having a range of Si:Al ratios, methods of preparing these and known crystalline microporous solids using certain quaternized imidazolium cation structuring agents. | ||||||
| 159 | Titanium silicalite molecular sieve and its synthesis | US14527657 | 2014-10-29 | US20150118149A1 | 2015-04-30 | Changjiu XIA; Bin ZHU; Min LIN; Xinxin PENG; Xingtian SHU; Chunfeng SHI |
| The present invention relates to a titanium silicalite molecular sieve, wherein the crystal grain of the titanium silicalite molecular sieve has a ratio of (surface Si/Ti ratio):(bulk Si/Ti ratio) being larger than 1.1 and less than 5. | ||||||
| 160 | SYNTHESIS OF BOROSILICATE TON-FRAMEWORK TYPE MOLECULAR SIEVES | US14051178 | 2013-10-10 | US20150104378A1 | 2015-04-16 | Matthew T. ARONSON; Tracy Margaret DAVIS |
| A method is disclosed for synthesizing borosilicate TON-framework type molecular sieves in a hydroxide media using a 1,3-dimethylimidazolium cation or a 1,4-bis(N-methylimidazolium)butane dication as a structure directing agent. | ||||||
QQ群二维码
意见反馈
意见反馈